Demonstrated clinical outcomes in an obesity subgroup population and consistent real-world evidence in patients who have NVAF and morbid obesity1,3,4

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

NVAF = nonvalvular atrial fibrillation; VTE = venous thromboembolism.